Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$6.32 USD
+0.53 (9.15%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $6.30 -0.02 (-0.32%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Aldeyra Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -37.54 | -62.02 | -57.78 | -37.55 | -60.83 |
Depreciation/Amortization & Depletion | 0.25 | 0.21 | 0.67 | 0.53 | -0.24 |
Net Change from Assets/Liabilities | 0.86 | -3.44 | 7.44 | -8.83 | 2.74 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.11 | 8.62 | 7.11 | 8.36 | 13.34 |
Net Cash From Operating Activities | -30.33 | -56.64 | -42.56 | -37.49 | -44.98 |
Property & Equipment | 0.00 | -0.02 | -0.01 | 0.00 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 |
Investments | 30.00 | -29.94 | 0.00 | 29.02 | 17.88 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 30.00 | -29.95 | -0.01 | 29.02 | 18.48 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.31 | 1.22 | 194.50 | 41.90 | 9.25 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 14.45 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.58 | 0.00 | 0.00 | 0.00 | -0.12 |
Net Cash from Financing Activities | -1.27 | 1.22 | 194.50 | 41.90 | 23.58 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.60 | -85.37 | 151.93 | 33.43 | -2.93 |
Cash at Beginning of Period | 144.42 | 229.79 | 77.86 | 44.43 | 47.36 |
Cash at End of Period | 142.82 | 144.42 | 229.79 | 77.86 | 44.43 |
Diluted Net EPS | -0.64 | -1.06 | -1.07 | -1.11 | -2.24 |
Fiscal Year End for Aldeyra Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -24.93 | -8.08 | -37.54 | -32.79 | -24.60 |
Depreciation/Amortization & Depletion | -0.57 | -0.11 | 0.25 | 0.18 | 0.12 |
Net Change from Assets/Liabilities | -1.27 | -3.39 | 0.86 | -5.06 | -4.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.58 | 1.61 | 6.11 | 6.84 | 5.95 |
Net Cash From Operating Activities | -23.20 | -9.97 | -30.33 | -30.83 | -22.80 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -48.61 | -30.38 | 30.00 | 30.00 | 30.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -48.61 | -30.38 | 30.00 | 30.00 | 30.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.02 | 0.02 | 0.31 | 0.28 | 0.06 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.58 | -0.53 | 0.00 |
Net Cash from Financing Activities | 0.02 | 0.02 | -1.27 | -0.26 | 0.06 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -71.79 | -40.33 | -1.60 | -1.08 | 7.26 |
Cash at Beginning of Period | 142.82 | 142.82 | 144.42 | 144.42 | 144.42 |
Cash at End of Period | 71.03 | 102.49 | 142.82 | 143.33 | 151.68 |
Diluted Net EPS | -0.28 | -0.14 | -0.08 | -0.14 | -0.15 |